We are collecting samples so they can be made available to future research scientists who hope to study the human body’s immune response to common infectious illness such as influenza or SARS-CoV-2. This means these samples can be used for other people’s research studies. Participants are healthy adults who have a history of coronavirus and/or influenza, vaccine history or lack thereof, and absence of immunocompromise. 
   

This clinical trial is for adults who have been diagnosed with a cancer called Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated CLL or SLL. 
   
Participants will be randomly assigned (like the flip of a coin) to receive study treatment with either BGB-16673 (Arm A of the study) or pirtobrutinib (Arm B).
   

This clinical trial is for adults who have an advanced solid tumor that has been treated with approved standard therapy and who have experienced disease progression following this prior treatment. The advanced solid tumor must be either non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), or head and neck squamous cell carcinoma (HNSCC).
   

 This clinical trial is for adults who have a confirmed diagnosis of solid tumor cancer associated with a risk of recurrence or progression (meaning that the cancer could come back or worsen).
   

This clinical trial is for adults who have advanced gastric, esophageal, or gastroesophageal junction (GEJ) cancer. The purpose of this study is to learn if the experimental drug denikitug (DEN) can help to control advanced gastric, esophageal, or GEJ cancer. The study will test DEN by itself and combined with other cancer drugs.
   
The study has two parts:
   --In Part 1, participants will be randomized (chosen by chance, like flipping a coin) to receive DEN alone or in combination with nivolumab (NIVO).

The purpose of this study is to find out if researchers can lower the chance of non-muscle invasive bladder cancer growing or spreading by using a combination of drugs called durvalumab and monalizumab. 
   
This combination of drugs has been tested in people with other cancers and was found to stabilize the cancer and stop it from spreading. However, the combination of durvalumab and monalizumab has not been tested in non-muscle invasive bladder cancer. 
   

The purpose of this study is to evaluate the safety and efficacy of IDE849 in participants with extensive stage small cell lung cancer (ES-SCLC), neuroendocrine carcinoma (NEC), and other delta-like protein 3 (DLL3)-expressing solid tumors.
   
IDE849 is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).
   
In this study, IDE849 will be given intravenously (meaning through a needle in the vein directly into the blood).

This study is for female and male patients who are 18 years of age and older, have a body mass index of 30-50 kg/m2 and have had difficulties losing weight or maintaining weight loss despite prior attempts with non-surgical weight-loss methods.

The purpose of this study to is to assess the feasibility and acceptability of using a point-of-care (POC) prostate specific antigen (PSA) test to screen men for prostate cancer in a community setting.

In this study, participants will receive a fingerstick blood draw from a research nurse at the barbershop and results will be shared with the participants.
   
Participation is expected to last up to 6 months.

The purpose of this study is to evaluate the safety and effectiveness of bright light therapy for patients with melanoma and non-small cell lung cancer (NSCLC).

In this study, bright light therapy will be provided via an iPad at the participant's home for 60 minutes total.
   
Participation is expected to last 3 weeks.